Supervisor – Konstantin Severinov, co-advisor Vladimir Ponomarev
Entry year to Skoltech – 2014
Education – I.M.Sechenov First Moscow State Medical University – Physician in the speciality of «General Medicine», National Research Center for Hematology – qualification “Hematology”.
M.D. (specialty in General Medicine) with diploma cum laude . l.M.Sechenov First Moscow State Medical University. Moscow, Russia
Clinical Residency (Hematology) National Research Center for Hematology Moscow, Russia.
Development and preclinical testing of CAR (Chimeric antigen receptor)-modified immune effector cells targeting acute myeloid leukemia in children.
Memorial Sloan Kettering Cancer Center, New York
The Vladimir Ponomarev Lab,
One of the most promising modern approaches to immunotherapy involves engineering patients’ own immune cells to recognize and attack their tumors, by transducing them with vectors carrying Chimeric Antigen Receptor (or receptors) to antigens specific to individual tumors. And although this approach, called adoptive cell transfer (ACT), has been restricted to small clinical trials so far, treatments using these engineered immune cells have generated some remarkable responses in patients with advanced cancer. For example, in several early-stage trials testing ACT in patients with advanced acute lymphoblastic leukemia (ALL) who had few if any remaining treatment options, many patients’ cancers have disappeared entirely. Several of these patients have remained cancer free for extended periods. Equally promising results have been reported in several small trials involving patients with lymphoma.
Our aim is to develop and test in vivo and in vitro CAR-T cells specific to Acute Myeloid Leukemia.
Participation in conferences.
World Molecular Imaging Congress (WMIC) 2016 Abstract & Poster “Imaging the efficacy of TRAIL-enhanced CAR T-cell immunotherapy”. New York. September 2016
World Molecular Imaging Congress (WMIC) 2016 Abstract & Poster “Concurrent and simultaneous multi-reporter bioluminescence imaging (BLI). New York. September 2016
“Chimeric antigene receptor (car)-t-cells therapy for cancer” “OMICS technologies in Clinical Oncology” Moscow, Russia. September 2016.
“U.M.N.l.K.” – «Reactivation of viral Hepatitis B and C in patients with hemoblastosis duting G-CSF Treatment”, November 2012.